Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s

4-Phenylbutyrate protects against rifampin-induced liver injury via regulating MRP2 ubiquitination through inhibiting endoplasmic reticulum stress

(2022) Jing Chen et al.   Bioengineered

Safety Evaluation of Antituberculosis Drugs During Pregnancy: A Systematic Review and Meta-Analysis

(2022) Xiaomei Zhou et al.   Frontiers in Surgery

Robust PBPK Model of Rifampicin for Predicting Drug‐Drug Interactions via P‐gp Induction and Inhibition in Intestine, Liver, and Kidney

(2022) Ryuta Asaumi et al.   CPT-Pharmacometrics & Systems Pharmacology

Tuberculosis Infection in Pregnant People: Current Practices and Research Priorities

(2022) Jyoti S. Mathad et al.   Pathogens

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women

(2021) Jyoti S Mathad et al.   CLINICAL INFECTIOUS DISEASES

Liver injury associated with drug intake during pregnancy

(2021) Priyanka Kamath et al.   World Journal of Hepatology

Fetomaternal Outcome of Pregnant Women Infected with Tuberculosis: An Analytical Study

(2021) Preeti F Lewis et al.   Journal of SAFOG

An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics

(2021) Ahizechukwu C. Eke   Journal of Basic and Clinical Physiology and Pharmacology

A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes

(2020) R. Perumal et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Pharmacokinetics and Drug‐Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping

(2020) Kamunkhwala Gausi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Increased risk of hepatotoxicity and temporary drug withdrawal during treatment of active tuberculosis in pregnant women

(2020) Josefine Beck-Friis et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Clinical Pharmacokinetics and Pharmacodynamics of Anti-Tubercular Drugs in Pregnancy

(2020) Jennifer R. Shiu et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis

(2019) M. Richardson et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

(2019) Ahmed Aliyu Abulfathi et al.   CLINICAL PHARMACOKINETICS

Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV

(2019) Mahmoud Tareq Abdelwahab et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The role of NAT2 polymorphism and methylation in anti‐tuberculosis drug‐induced liver injury in Mongolian tuberculosis patients

(2019) Dong Zhang et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid

(2018) Maxwell T Chirehwa et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Tuberculosis during pregnancy in the United States: Racial/ethnic disparities in pregnancy complications and in-hospital death

(2018) Erika M. Dennis et al.   PLoS One

A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs

(2018) Alper Daskapan et al.   CLINICAL PHARMACOKINETICS

Kidney function during pregnancy: a systematic review and meta-analysis

(2018) Veronica A. Lopes van Balen et al.   ULTRASOUND IN OBSTETRICS & GYNECOLOGY

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

(2017) Martin J Boeree et al.   LANCET INFECTIOUS DISEASES

Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis

(2016) S Sobhy et al.   BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY

Tuberculosis Disease during Pregnancy and Treatment Outcomes in HIV-Infected and Uninfected Women at a Referral Hospital in Cape Town

(2016) Adrie Bekker et al.   PLoS One

Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters

(2016) Lindsey H.M. te Brake et al.   TUBERCULOSIS

The challenges of pharmacokinetic variability of first-line anti-TB drugs

(2016) Bella Devaleenal Daniel et al.   Expert Review of Clinical Pharmacology

Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa

(2015) Paolo Denti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi

(2015) J. J. van Oosterhout et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania

(2015) Paolo Denti et al.   PLoS One

Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis

(2014) Emmanuel Chigutsa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Factors Associated with Variability in Rifampin Plasma Pharmacokinetics and the Relationship between Rifampin Concentrations and Induction of Efavirenz Clearance

(2014) Awewura Kwara et al.   PHARMACOTHERAPY

The neglected global burden of tuberculosis in pregnancy

(2014) Alimuddin Zumla et al.   Lancet Global Health

Tuberculosis in pregnancy: an estimate of the global burden of disease

(2014) Jordan Sugarman et al.   Lancet Global Health

Pharmacokinetics of First-Line Tuberculosis Drugs in Tanzanian Patients

(2013) Alma Tostmann et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isoniazid, Rifampin, and Pyrazinamide Plasma Concentrations in Relation to Treatment Response in Indonesian Pulmonary Tuberculosis Patients

(2013) Erlina Burhan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants

(2013) Tanis R Fenton et al.   BMC Pediatrics

Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

(2013) J. G. Pasipanodya et al.   JOURNAL OF INFECTIOUS DISEASES

Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines

(2012) Helen McIlleron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A case–control study of the risk of adverse perinatal outcomes due to tuberculosis during pregnancy

(2012) B. Asuquo et al.   JOURNAL OF OBSTETRICS AND GYNAECOLOGY

Risk of Tuberculosis in Pregnancy

(2011) Dominik Zenner et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients

(2011) Justin J. Wilkins et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pyrazinamide pharmacokinetics and efficacy in adults and children

(2011) P.R. Donald et al.   TUBERCULOSIS

Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV‐Infected Cohort of Adults with Tuberculosis from Botswana

(2009) Sekai Chideya et al.   CLINICAL INFECTIOUS DISEASES

Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review

(2007) Alma Tostmann et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY